{"id":384,"date":"2025-10-17T07:30:24","date_gmt":"2025-10-17T07:30:24","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=384"},"modified":"2025-10-17T07:38:47","modified_gmt":"2025-10-17T07:38:47","slug":"china-bd-2025-hansoh-and-roche-enters-a-license-on-cdh17-targeting-adc-hs-20110","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/384.html","title":{"rendered":"[China BD 2025] Hansoh and Roche enters a 1.53 Billion USD License on CDH17 ADC HS-20110"},"content":{"rendered":"\n<p>Announced Date: 2025-10-17 (October 17, 2025)<\/p>\n\n\n\n<p>Licensor (Seller):  Hansoh Pharma (China)<\/p>\n\n\n\n<p>Licensee (Buyer): \u00a0Roche<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Name: HS-20110<\/p>\n\n\n\n<p>Asset Modality: Antibody-drug conjugate (ADC)\u00a0<\/p>\n\n\n\n<p>Antibody Target: Humanized anti-CDH17 monoclonal antibody\u00a0<\/p>\n\n\n\n<p>ADC Payload:  Validated topoisomerase inhibitor (TOPOi) payload<\/p>\n\n\n\n<p>Potential Indication: Solid tumors including colorectal cancer (CRC)<\/p>\n\n\n\n<p>Current Stage: Global \u00a0Phase I trial underway in China and the United States<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Hansoh Pharma grants Roche an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan) to progress the clinical development and commercialization of HS-20110.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Hansoh Pharma\u00a0will receive:<\/p>\n\n\n\n<p>an upfront payment of US$80 million,<\/p>\n\n\n\n<p>up to US$ 1.45 billion milestone payments, <\/p>\n\n\n\n<p>royalties on potential future product sales.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.hspharm.com\/news\/news-detail-513371.htm\">HANSOH GRANTS ROCHE AN EXCLUSIVE LICENSE TO NOVEL CDH17-TARGETING ADC HS-20110-Press Releases-Hansoh Pharmaceutical Group Co., Ltd. (hspharm.com)<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of Hansoh Pharma, \u701a\u68ee\u5236\u836f\u3001\u8c6a\u68ee\u836f\u4e1a<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-10-17 (October 17, 2025) Licensor (Seller): Hansoh Pharma (China) Licensee (Buyer): \u00a0Roche . Asset &hellip; <a title=\"[China BD 2025] Hansoh and Roche enters a 1.53 Billion USD License on CDH17 ADC HS-20110\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/384.html\"><span class=\"screen-reader-text\">[China BD 2025] Hansoh and Roche enters a 1.53 Billion USD License on CDH17 ADC HS-20110<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-384","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=384"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/384\/revisions"}],"predecessor-version":[{"id":387,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/384\/revisions\/387"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=384"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=384"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}